We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Advanced Medical Solutions Group Plc | LSE:AMS | London | Ordinary Share | GB0004536594 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.40 | 1.24% | 195.40 | 194.80 | 195.60 | 195.60 | 192.00 | 192.40 | 342,131 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Plastics,resins,elastomers | 126.21M | 15.89M | 0.0732 | 26.67 | 424M |
From May 2019 to May 2024
TIDMAMS
RNS Number : 7430K
Advanced Medical Solutions Grp PLC
18 December 2018
18 December 2018
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Trading Update
Winsford, UK, 18 December 2018: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, today announces an update on trading for the year ending 31 December 2018.
The Group continues to make good progress and the Board expects results to be in line with current market expectations.
Chris Meredith, Chief Executive Officer of AMS, said: "The Group continues to deliver good growth supported by innovative product development and is well positioned for the future."
The Group expects to publish its Preliminary Results for the year to 31 December 2018 in March 2019.
- End -
For further information, please contact:
Hot Features
Premium
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Mary Tavener, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Nicholas
Brown / Olivia Manser
Investec Bank plc (NOMAD) & Broker Tel: +44 (0) 20 7597
5970
Daniel Adams / Gary Clarence / Patrick
Robb
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of products that include tissue adhesives, sutures, haemostats, internal fixation devices, silver alginates, alginates and foams, which it markets under its brands LiquiBand(R) , RESORBA(R) , LiquiBand(R) Fix8(TM) and ActivHeal(R) as well as supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 77 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 650 employees. For more information please see www.admedsol.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
TSTLLFIDFSLDLIT
(END) Dow Jones Newswires
December 18, 2018 02:00 ET (07:00 GMT)
1 Year Advanced Medical Solutions Chart |
1 Month Advanced Medical Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
